A company information session will be held Wednesday, December 4, 2024in 1:00 PM ET
new haven, connecticut, November 21, 2024 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI) is developing an investigational drug, Haduvio™ (oral nalbuphine ER), for the treatment of patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough. is a clinical-stage biopharmaceutical company. Chronic Cough (RCC) announced today: jennifer goodPresident and CEO, Piper Sandler speaks at the 36th Annual Healthcare Conference. Wednesday, December 4thin 1pm ET. Held from December 3rd – December 5th in new yorkMr. Good and Chief Financial Officer Delfini will also participate in an investor meeting with event attendees. Presentations and meetings are open to direct attendees.
About Trevi Therapeutics
Trevi Therapeutics, Inc. is developing an investigational drug, Haduvio™ (oral nalbuphine extended-release formulation), for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). is a biopharmaceutical company. Haduvio acts both centrally and peripherally in the cough reflex arc as a kappa agonist and mu antagonist (KAMA), an opioid receptor that plays an important role in controlling cough hypersensitivity. Nalbuphine is currently not scheduled by the U.S. Drug Enforcement Administration.
Chronic cough is highly prevalent among the approximately 140,000 IPF patients in the United States, with up to 85% of IPF patients experiencing chronic cough. The impact of chronic cough is significant, with some IPF patients coughing up to 1,500 times per day, which can lead to worsening of the disease, increased risk of progression, death, or the need for a lung transplant. Chronic cough also often leads to decreased social, physical, and psychological quality of life for patients. There are no treatments approved for the treatment of chronic cough in IPF, and current off-label treatment options provide minimal benefit to patients.
Intractable chronic cough affects approximately 2 to 3 million adults in the United States and is caused by cough reflex hypersensitivity in both the central and peripheral nervous systems. This is highly devastating and is associated with a wide range of complications, from urinary incontinence in women to sleep disturbances and social embarrassment that causes significant social and economic burdens for patients and those around them. Haduvio is being developed for the treatment of moderate to severe RCC. There is also no approved treatment for RCC in the United States.
Trevi plans to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and effectiveness have not been evaluated by any regulatory agency.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor contact information
katie valet
trevi Therapeutics Co., Ltd.
203-304-2499
(email protected)
media contact
Rosalia Scampoli
914-815-1465
(email protected)
SOURCE Trevi Therapeutics, Inc.
I want company news Have you been featured on PRNEWSWIRE.COM?
Over 440,000
newsroom and
influencer
9k+
digital media
outlet
Over 270,000
journalist
opt-in
